These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30190545)

  • 1. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
    Traboulsi T; El Ezzy M; Dumeaux V; Audemard E; Mader S
    Oncogene; 2019 Feb; 38(7):1019-1037. PubMed ID: 30190545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
    Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
    J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C; Leone S; Bianchi F; Acconcia F
    Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
    Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
    J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
    Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
    Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
    Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
    Traboulsi T; El Ezzy M; Gleason JL; Mader S
    J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
    Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
    PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
    J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
    Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of SUMOylation in full antiestrogenicity.
    Hilmi K; Hussein N; Mendoza-Sanchez R; El-Ezzy M; Ismail H; Durette C; Bail M; Rozendaal MJ; Bouvier M; Thibault P; Gleason JL; Mader S
    Mol Cell Biol; 2012 Oct; 32(19):3823-37. PubMed ID: 22826433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.